NASDAQ · QNTM
Quantum Biopharma financials
$3.82−3.54%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 |
| Gross margin | — | — |
| Operating income | -$15.3M | -$16.1M |
| Net income | -$27.0M | -$14.9M |
| Net margin | — | — |
| Diluted EPS | $-8.20 | $-13.12 |
| EBITDA | -$14.8M | -$15.6M |
| Operating cash flow | -$8.2M | -$6.9M |
| Free cash flow | -$8.2M | -$6.9M |
| Diluted shares | 3.3M | 1.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 |
|---|---|---|
| Cash & equivalents | $1.9M | $6.0M |
| Short-term investments | $459.1K | $1.2M |
| Total debt | $1.8M | $771.1K |
| Total assets | $11.2M | $17.1M |
| Total liabilities | $6.1M | $6.7M |
| Shareholders' equity | $5.1M | $10.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology